Panelists discuss the clinical presentation and burden of disease of generalized pustular psoriasis, focusing on its severe, debilitating symptoms and the significant impact it has on patients’ quality of life, highlighting the need for effective treatment options.

Panelists discuss the physical and mental health challenges of generalized pustular psoriasis (GPP), common flare triggers, the varying severity of flares, and the importance of timely treatment to prevent severe complications.

Panelists discuss their typical approach to diagnosing generalized pustular psoriasis (GPP), including key clinical features and how they distinguish GPP from other psoriatic conditions such as plaque psoriasis based on presentation and diagnostic criteria.

Panelists discuss the biggest challenges dermatologists face in diagnosing generalized pustular psoriasis (GPP), focusing on the heterogeneity of patient presentations and how this complicates the diagnosis. They also explore how the relative rarity of GPP, compared with other psoriatic conditions, contributes to delays in diagnosis and treatment. They also examine the impact of misdiagnosis or delayed diagnosis on patient outcomes.

Panelists discuss recent advances in understanding the pathogenesis of generalized pustular psoriasis (GPP) and how these insights have influenced the approach to and management of the disease. They also outline their immediate and long-term treatment goals for patients with GPP, focusing on symptom control and long-term disease management.

Panelists discuss the general treatment approach for generalized pustular psoriasis (GPP) prior to the availability of FDA-approved agents with specific indications, examining how these treatments aligned with patient goals and identifying the unmet needs that remained in managing the disease.

Panelists discuss the importance of multidisciplinary care in managing generalized pustular psoriasis (GPP), including collaboration between dermatologists and other specialists, and explore strategies for addressing the psychosocial aspects of treatment to improve overall patient outcomes.

Panelists describe the role of the IL-36 pathway in the pathogenesis of generalized pustular psoriasis (GPP) and discuss how IL-36 inhibition can be a key strategy in managing the disease.

Panelists provide an overview of spesolimab, an IL-36R inhibitor now FDA-approved for treating GPP, discussing the efficacy and safety data from the EFFISAYIL-1 trial (intravenous [IV] formulation) and the EFFISAYIL-2 trial (subcutaneous [SQ] formulation).

Panelists compare the results of the EFFISAYIL-1 and -2 trials with real-world use of spesolimab; discuss treatment expectations with patients; and explore the similarities, differences, and management roles of intravenous (IV) and subcutaneous (SQ) formulations, with strategies for timely IV therapy initiation during flares.

Panelists discuss spesolimab’s place in therapy for treating generalized pustular psoriasis (GPP), address remaining unmet treatment needs, and share the types of future data they would like to see, along with key takeaways and advice for dermatologists managing patients with GPP.